Comparison of select GvHD prevention approaches in transplant for hematologic malignancies
| Approach . | Severe aGvHD . | cGvHD . | Graft failure . | Relapse . | Immune reconstitution/ viral infections . | Optimal use . |
|---|---|---|---|---|---|---|
| Abatacept | Decreased | No impact | No impact | No impact observed | No impact/increased reactivation without severe disease | Unrelated donor (especially mismatched) |
| Posttransplant cyclophosphamide | Decreased | Decreased | Possibly increased | Increased in some studies | Delayed in some studies/ increased grade 2 infections | Unrelated, haploidentical |
| Selective ex vivo graft manipulation | Decreased | Decreased | Increased | No impact observed | Varies by approach, enhanced related to other T-cell depletion approaches | Unrelated, haploidentical (clinical trial) |
| Approach . | Severe aGvHD . | cGvHD . | Graft failure . | Relapse . | Immune reconstitution/ viral infections . | Optimal use . |
|---|---|---|---|---|---|---|
| Abatacept | Decreased | No impact | No impact | No impact observed | No impact/increased reactivation without severe disease | Unrelated donor (especially mismatched) |
| Posttransplant cyclophosphamide | Decreased | Decreased | Possibly increased | Increased in some studies | Delayed in some studies/ increased grade 2 infections | Unrelated, haploidentical |
| Selective ex vivo graft manipulation | Decreased | Decreased | Increased | No impact observed | Varies by approach, enhanced related to other T-cell depletion approaches | Unrelated, haploidentical (clinical trial) |